NovoCure Ltd — Director's Dealing 2019

Sep 3, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-08-29

Reporting Person: Danziger Asaf (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-29	Ordinary Shares	S	57913	$90.577	Disposed	200869	Direct
2019-08-29	Ordinary Shares	S	65768	$91.604	Disposed	135101	Direct
2019-08-29	Ordinary Shares	S	500	$92.00	Disposed	134601	Direct

Footnotes

F1: On August 29, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 57,913 shares in multiple trades at prices ranging from $90.00 to $90.995. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F2: On August 29, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 65,768 shares in multiple trades at prices ranging from $91.00 to $91.99. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.